UNCY — Unicycive Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1766140 ·
Last close
$4.70
Market Cap
$128.61M
52W High
$8.74
52W Low
$3.75
ADV30
767,593
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,140,000 | -1,722,000 | 72,029,000 | 44,185,000 | 18,759,000 |
| Mar 2026 | 0 | — | -8,437,000 | -12,823,000 | 64,406,000 | 37,371,000 | 26,702,000 |
| Dec 2025 | 0 | — | -7,224,000 | -14,668,000 | 49,135,000 | 29,198,000 | 18,938,000 |
| Sep 2025 | 0 | — | -7,342,000 | -6,011,000 | 50,611,000 | 42,695,000 | 13,131,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,655,000
Investing CF
$-17,234,000
Financing CF
$63,491,000
CapEx
$-32,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.89
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-140,648,000
Inventory
—
Receivables
—
ST Investments
$17,215,000
EBIT TTM
$-39,894,000
Pretax Income TTM
$-39,949,000
Interest Exp TTM
$55,000
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,517,000 | -26,555,000 | 49,135,000 | 18,938,000 | 30,197,000 | -31,317,000 |
| Dec 2024 | 0 | -32,117,000 | -36,729,000 | 31,668,000 | 24,237,000 | 7,431,000 | -28,575,000 |
| Dec 2023 | 675,000 | -20,774,000 | -30,544,000 | 14,191,000 | 18,000,000 | -3,809,000 | -18,283,000 |
| Dec 2022 | 951,000 | -18,052,000 | -18,058,000 | 2,818,000 | 3,284,000 | -466,000 | -15,651,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.66
Max Pain — expiry 2027-02-19
max pain strike: $2.50 · spot: $4.70 · call oi: 4,539 · put oi: 527
Expected Move to 2027-02-19:
±$2.30
(48.99%) —
implied range
$2.40 –
$7.00
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLSA | Tiziana Life Sciences Ltd | $128.53M | $1.01 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $129.67M | $2.99 | — |
| IMUX | IMMUNIC, INC. | $127.51M | $9.35 | — |
| MNOV | MEDICINOVA INC | $126.99M | $2.58 | — |
| HURA | TuHURA Biosciences, Inc./NV | $133.83M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
2026-08-12 12:00 · Yahoo
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
2026-07-01 22:13 · Yahoo
Top Midday Decliners
2026-06-30 18:41 · Yahoo
Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)
2026-06-30 12:42 · Yahoo
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
2026-06-30 11:05 · Yahoo
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?
2026-05-14 23:19 · Yahoo
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 11:05 · Yahoo
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
2026-03-30 11:05 · Yahoo
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-09 11:05 · Yahoo
Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
2026-08-05 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.